TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2845199

Group type: EXPERIMENTAL
Intervention: Deferoxamine (30 mg/kg IV before and after bypass, 250 mg/L in cardioplegic solution)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no deferoxamine)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Deferoxamine and Control
Number of subjects: 24
Study: 31621901

Group type: EXPERIMENTAL
Intervention: Intervention (INT) - Geriatric Acute and Post-Acute Fall Prevention Intervention (GAPcare) including medication therapy management by a pharmacist and fall risk assessment by a physical therapist.
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control (UC) - Usual care (no specific intervention details provided).
Number of subjects: 110
Study: 31337525

Group type: EXPERIMENTAL
Intervention: Catheter ablation (CA) with anticoagulant therapy using edoxaban
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard medication
Number of subjects: 250
Study: 28991711

Group type: EXPERIMENTAL
Intervention: Tremor's glove (EMS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham glove
Number of subjects: 30
Study: 26538411

Group type: EXPERIMENTAL
Intervention: Pursed-lips breathing during TGlittre test
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pursed-lips breathing during 6MWT
Number of subjects: 25

Group type: COMPARATOR
Intervention: Non-Pursed-lips breathing during 6MWT
Number of subjects: 25

Group type: COMPARATOR
Intervention: Non-Pursed-lips breathing during TGlittre test
Number of subjects: 25
Study: 23169292

Group type: EXPERIMENTAL
Intervention: gemcitabine/erlotinib followed by capecitabine
Number of subjects: 208

Group type: COMPARATOR
Intervention: capecitabine/erlotinib followed by gemcitabine
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: PTEN loss
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: KRAS wild-type
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: EGFR overexpression
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: EGFR gene amplification
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Skin rash occurrence
Number of subjects: 208
Study: 16937848

Group type: EXPERIMENTAL
Intervention: Midazolam plus Ketamine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 120

Group type: COMPARATOR
Intervention: Ketamine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Zolpidem
Number of subjects: 120

Group type: COMPARATOR
Intervention: Midazolam plus Tramadol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Zolpidem plus Tramadol
Number of subjects: 120
Study: 14518608

Group type: EXPERIMENTAL
Intervention: L-arginine (8 g p.o. two times daily) for 14 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: L-arginine (8 g p.o. two times daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: L-arginine supplementation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Baseline ADMA levels
Number of subjects: 12

Group type: COMPARATOR
Intervention: L-arginine and placebo
Number of subjects: 12
Study: 10830415

Group type: EXPERIMENTAL
Intervention: tolcapone (50 mg, 200 mg, or 400 mg three times a day)
Number of subjects: 46

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 46
Study: 9014744

Group type: EXPERIMENTAL
Intervention: Intravenous clodronate (1800 mg) combined with MivP chemotherapy
Number of subjects: 211

Group type: COMPARATOR
Intervention: MivP chemotherapy alone
Number of subjects: 211

Group type: COMPARATOR
Intervention: Lower doses of intravenous clodronate combined with MivP
Number of subjects: 211
Study: 1502991

Group type: EXPERIMENTAL
Intervention: Surgery based on prism adapted angle in 31 prism responders
Number of subjects: 77

Group type: COMPARATOR
Intervention: Surgery for initially measured angle in 32 prism responders
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Surgery for preoperative measured angle in 14 non-responders
Number of subjects: 77
Study: 6507825

Group type: EXPERIMENTAL
Intervention: Atropine 1.2 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Glycopyrronium 0.6 mg
Number of subjects: 8
Study: 31993783

Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide (PEA)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 30342697

Group type: EXPERIMENTAL
Intervention: Once weekly dressing changes with negative pressure wound therapy (NPWT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Thrice weekly dressing changes with negative pressure wound therapy (NPWT)
Number of subjects: 44
Study: 28007665

Group type: EXPERIMENTAL
Intervention: Daclizumab 0.3 mg/kg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Daclizumab 1.2 mg/kg
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 26139733

Group type: EXPERIMENTAL
Intervention: Propofol 1 mg/kg IV bolus followed by 0.5 mg/kg (Group P)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Etomidate 0.1 mg/kg followed by 0.05 mg/kg (Group E)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 60
Study: 23831409

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM) intervention
Number of subjects: 126

Group type: COMPARATOR
Intervention: Usual Treatment (UT)
Number of subjects: 126
Study: 21079105

Group type: EXPERIMENTAL
Intervention: Endoscopic brow-lift (EBL)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Open brow-lift (OBL)
Number of subjects: 21
Study: 19103991

Group type: EXPERIMENTAL
Intervention: Vigorous physical activity (active > or =1 to 3 times a month)
Number of subjects: 21094

Group type: EXPERIMENTAL
Intervention: BMI increase (per 1-kg/m(2) increment)
Number of subjects: 21094

Group type: COMPARATOR
Intervention: Overweight participants (BMI 25 to 29.9 kg/m(2)) compared to lean participants (BMI <25 kg/m(2))
Number of subjects: 21094

Group type: COMPARATOR
Intervention: Obese participants (BMI > or =30 kg/m(2)) compared to lean participants (BMI <25 kg/m(2))
Number of subjects: 21094

Group type: COMPARATOR
Intervention: Lean active men (reference group)
Number of subjects: 21094

Group type: COMPARATOR
Intervention: Lean inactive men compared to lean active men
Number of subjects: 21094

Group type: COMPARATOR
Intervention: Overweight active men compared to lean active men
Number of subjects: 21094

Group type: COMPARATOR
Intervention: Overweight inactive men compared to lean active men
Number of subjects: 21094

Group type: COMPARATOR
Intervention: Obese active men compared to lean active men
Number of subjects: 21094

Group type: COMPARATOR
Intervention: Obese inactive men compared to lean active men
Number of subjects: 21094
Study: 17872784

Group type: EXPERIMENTAL
Intervention: Canalith repositioning maneuver (CRM)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Sham maneuver
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Both groups (CRM and Sham)
Number of subjects: 81
Study: 15203886

Group type: EXPERIMENTAL
Intervention: Nicotinamide 50 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11466137

Group type: EXPERIMENTAL
Intervention: 100 mg of rt-PA
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: COMPARATOR
Intervention: No ST variability
Number of subjects: 102
Study: 9479357

Group type: EXPERIMENTAL
Intervention: TOR 60 mg daily
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: TOR 240 mg daily
Number of subjects: 463

Group type: COMPARATOR
Intervention: TAM 40 mg daily
Number of subjects: 463
Study: 7931484

Group type: EXPERIMENTAL
Intervention: VCR, AMD, and radiation therapy
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: VCR, AMD, DOX, and radiation therapy
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Regimen DD-RT (VCR, AMD, without DOX)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Regimen J (VCR, AMD, DOX)
Number of subjects: 66
Study: 2979259

Group type: EXPERIMENTAL
Intervention: 35 micrograms enprostil b.d. for up to 6 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: 400 mg cimetidine b.d. for up to 6 weeks
Number of subjects: 120
Study: 29500310

Group type: EXPERIMENTAL
Intervention: Once-weekly somapacitan
Number of subjects: 92

Group type: COMPARATOR
Intervention: Once-daily Norditropin
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 92
Study: 28211028

Group type: EXPERIMENTAL
Intervention: rhGH administration (0.029 mg kg-1 BW; 6 days/week for 3 weeks)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: rhGH administration
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study: 26303912

Group type: EXPERIMENTAL
Intervention: Mindfulness-based Cognitive Therapy (MBCT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 44
Study: 23264611

Group type: EXPERIMENTAL
Intervention: Supervised toothbrushing in nurseries and distribution of fluoride toothpaste and toothbrushes for home use
Number of subjects: 99071

Group type: EXPERIMENTAL
Intervention: Uptake of toothbrushing
Number of subjects: 99071

Group type: EXPERIMENTAL
Intervention: Uptake of toothbrushing (excluding one outlying Health Board)
Number of subjects: 99071
Study: 22014339

Group type: EXPERIMENTAL
Intervention: Saphenous vein grafts
Number of subjects: 210

Group type: COMPARATOR
Intervention: Right gastroepiploic artery grafts
Number of subjects: 210

Group type: COMPARATOR
Intervention: Right internal thoracic artery grafts
Number of subjects: 210
Study: 18716528

Group type: EXPERIMENTAL
Intervention: Group A (8 mm Hg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Group B (12 mm Hg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Group C (15 mm Hg)
Number of subjects: 45
Study: 16921052

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/d
Number of subjects: 7154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7154

Group type: EXPERIMENTAL
Intervention: Tamoxifen with HRT
Number of subjects: 7154

Group type: COMPARATOR
Intervention: Placebo with HRT
Number of subjects: 7154

Group type: COMPARATOR
Intervention: HRT started in first 6 months (Placebo)
Number of subjects: 7154

Group type: EXPERIMENTAL
Intervention: HRT started in first 6 months (Tamoxifen)
Number of subjects: 7154
Study: 14627063

Group type: EXPERIMENTAL
Intervention: Short-term naltrexone (NTX) for 3 months
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Long-term naltrexone (NTX) for 12 months
Number of subjects: 627

Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: All groups (short-term NTX, long-term NTX, placebo)
Number of subjects: 627
Study: 11124554

Group type: EXPERIMENTAL
Intervention: Stapled anastomoses
Number of subjects: 63

Group type: COMPARATOR
Intervention: Hand-sewn anastomoses
Number of subjects: 63
Study: 9085026

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine treatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (water treatment)
Number of subjects: 8
Study: 1496507

Group type: EXPERIMENTAL
Intervention: Drainage bags (56 patients, 87 drains)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Underwater seal drains (63 patients, 98 drains)
Number of subjects: 119
Study: 3996841

Group type: EXPERIMENTAL
Intervention: Cimetidine, two doses of 400 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cimetidine, four doses of 400 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ranitidine, two doses of 150 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ranitidine, two doses of 300 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 30878897

Group type: EXPERIMENTAL
Intervention: Intravenous labetalol (20 mg initially, escalating doses up to 300 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Oral nifedipine (10 mg initially, escalating doses up to 90 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Oral nifedipine
Number of subjects: 120
Study: 30425104

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure (BP) control
Number of subjects: 2486
Study: 26215362

Group type: EXPERIMENTAL
Intervention: bioDensity (bD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: bioDensity (bD) + Power Plate (PP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Power Plate (PP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: bioDensity (bD), Power Plate (PP), and bioDensity + Power Plate (bD+PP)
Number of subjects: 60
Study: 24168291

Group type: EXPERIMENTAL
Intervention: 1-ml injection of platelet-rich plasma (PRP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 1-ml injection of platelet-poor plasma (PPP)
Number of subjects: 60
Study: 22045605

Group type: EXPERIMENTAL
Intervention: Basic Life Support (BLS) education
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Feedback from CPR team leaders
Number of subjects: 92
Study: 20189753

Group type: EXPERIMENTAL
Intervention: IV paracetamol 1 g every 6 hours and IV meperidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: IV meperidine
Number of subjects: 40
Study: 18050629

Group type: EXPERIMENTAL
Intervention: Electro-superficial-acupuncture (ESA) at Sanyinjiao (SP6) with electric stimulation (60 Hz, 2-3 V) for 30 min
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Superficial acupuncture (SA) at Sanyinjiao (SP6)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Medication group (Brufen sustained-release capsules, 0.3 mg, b.i.d. for 3 days)
Number of subjects: 171
Study: 15591725

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (AC) following the guidelines of the German Cancer Society (GCS)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) chemotherapy
Number of subjects: 133
Study: 11932132

Group type: EXPERIMENTAL
Intervention: Specific acupuncture
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Nonspecific acupuncture
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Symptom based acupuncture
Number of subjects: 503

Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Acupuncture (all types)
Number of subjects: 503
Study: 10498373

Group type: EXPERIMENTAL
Intervention: Cyclic indentation tests on soft tissues of residual limbs
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Force relaxation studies
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cyclic indentation tests
Number of subjects: 10
Study: 8950740

Group type: EXPERIMENTAL
Intervention: Low-fat peptide-based diet
Number of subjects: 14

Group type: COMPARATOR
Intervention: High-fat peptide-based diet
Number of subjects: 14
Study: 2033353

Group type: EXPERIMENTAL
Intervention: Coagulation (Ultroid, Microvasive Inc., USA)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Injection sclerotherapy
Number of subjects: 51
Study: 6171099

Group type: EXPERIMENTAL
Intervention: Intranasal administration of 5 mg polyguacyl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aerosol administration of polyguacyl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intranasal administration of live influenza A (H1N1) vaccine
Number of subjects: 0
Study: 31278462

Group type: EXPERIMENTAL
Intervention: ACTION Respecting Choices ACP intervention
Number of subjects: 442
Study: 29673333

Group type: EXPERIMENTAL
Intervention: Community health worker intervention consisting of setting health goals, health education, activation for doctor's appointments, and referrals to DM prevention programs.
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Community health worker intervention
Number of subjects: 2000
Study: 28432794

Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 249
Study: 26071951

Group type: EXPERIMENTAL
Intervention: High-efficiency on-line hemodiafiltration (OL-HDF)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Low-flux hemodialysis (LF-HD)
Number of subjects: 130
Study: 23466353

Group type: EXPERIMENTAL
Intervention: 6% coriander oil in unguentum leniens applied twice daily
Number of subjects: 40
Study: 21174098

Group type: EXPERIMENTAL
Intervention: 1.0 M gadobutrol
Number of subjects: 41

Group type: COMPARATOR
Intervention: 0.5 M gadoterate
Number of subjects: 41
Study: 18312872

Group type: EXPERIMENTAL
Intervention: Mandibular repositioning splint (MRS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (CPAP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Neither treatment
Number of subjects: 20
Study: 16584436

Group type: EXPERIMENTAL
Intervention: Aprotinin (AP) 280 mg followed by 70 mg per hour
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 40 mg per kg followed by 40 mg per kg per hour
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (historical)
Number of subjects: 51
Study: 12493139

Group type: EXPERIMENTAL
Intervention: Physician advice fat-reduced diet
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Dietitian advice fat-reduced diet
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Dietitian advice soluble fibre-enhanced diet
Number of subjects: 111
Study: 9818633

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 35
Study: 7663593

Group type: EXPERIMENTAL
Intervention: Heated wire humidification circuits
Number of subjects: 140

Group type: COMPARATOR
Intervention: Heat and moisture exchanger circuits
Number of subjects: 140
Study: 2654454

Group type: EXPERIMENTAL
Intervention: Suction-cup oculopression (SOP) at negative pressure - 110 mm Hg for average 26 min
Number of subjects: 44

Group type: COMPARATOR
Intervention: Vörösmarthy oculopression (VOP) at level of oculopression 30 mm Hg for average 26 min
Number of subjects: 44

Group type: COMPARATOR
Intervention: Vörösmarthy oculopression (VOP)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Suction-cup oculopression (SOP)
Number of subjects: 44
Study: 53548

Group type: EXPERIMENTAL
Intervention: Prophylactic oral metronidazole and kanamycin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dietary and mechanical preparation alone
Number of subjects: 50
Study: 7386225

Group type: EXPERIMENTAL
Intervention: Ampicillin in a daily dose of 30 g for three days and 20 g for four days (excessive doses)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional therapy (moderate doses of ampicillin for one month)
Number of subjects: 34
Study: 31029650

Group type: EXPERIMENTAL
Intervention: Low FODMAP diet
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control diet (sham diet)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control diet (habitual diet)
Number of subjects: 130
Study: 31671584

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Circuit Training (HIICT)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 54
Study: 29617814

Group type: EXPERIMENTAL
Intervention: DPX-RSV(A) 10-μg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: DPX-RSV(A) 25-μg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: RSV(A)-Alum
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 26590516

Group type: EXPERIMENTAL
Intervention: Active tDCS stimulation in PWS
Number of subjects: 10
Study: 25064249

Group type: EXPERIMENTAL
Intervention: Bipolar voltage (BiV) mapping with a cutoff value of 0.45 mV for the left pulmonary vein-left atrial appendage (LAA-LPV) ridge and 0.2 mV for other localizations in first time PVI.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bipolar voltage (BiV) mapping with a cutoff value of 0.2 mV for the LAA-LPV ridge and 0.15 mV for other localizations in redo PVI.
Number of subjects: 30
Study: 23249758

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate 150 mg/day from day 3 to day 7 of the cycle (n=145)
Number of subjects: 291

Group type: COMPARATOR
Intervention: High doses of gonadotropins (GnRH agonist 0.1 mg and recombinant FSH 450 IU daily) (n=146)
Number of subjects: 291
Study: 19169912

Group type: EXPERIMENTAL
Intervention: Triamcinolone cream
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 50
Study: 17684087

Group type: EXPERIMENTAL
Intervention: Pelvic-floor muscle (PFM) strength assessed by the Brink scale
Number of subjects: 643
Study: 15007566

Group type: EXPERIMENTAL
Intervention: Infradiaphragmatic 18F‐fluorodeoxyglucose (FDG) uptake identified by PET/CT
Number of subjects: 1241

Group type: EXPERIMENTAL
Intervention: Increased FDG uptake in abdominal fatty tissue identified by PET/CT
Number of subjects: 1241

Group type: EXPERIMENTAL
Intervention: Benign supradiaphragmatic uptake pattern
Number of subjects: 1241

Group type: EXPERIMENTAL
Intervention: PET/CT imaging
Number of subjects: 1241
Study: 12139205

Group type: EXPERIMENTAL
Intervention: 10 mg once daily (OD) alfuzosin
Number of subjects: 18

Group type: COMPARATOR
Intervention: 2.5 mg three times daily (TID) alfuzosin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Comparison of both formulations
Number of subjects: 18
Study: 10211264

Group type: EXPERIMENTAL
Intervention: Didactic computer material
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Problem-based computer material
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Free text response computer material
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no computer material)
Number of subjects: 90
Study: 7840365

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cognitive Behavior Therapy
Number of subjects: 18
Study: 1697914

Group type: EXPERIMENTAL
Intervention: YM617 0.4 mg
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: YM617 0.2 mg
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: YM617 0.1 mg
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study: 671684

Group type: EXPERIMENTAL
Intervention: Mechanical chest compression
Number of subjects: 50

Group type: COMPARATOR
Intervention: Manual chest compression
Number of subjects: 50
Study: 30589338

Group type: EXPERIMENTAL
Intervention: Second Step program
Number of subjects: 8941

Group type: COMPARATOR
Intervention: Control group (wait-list)
Number of subjects: 8941
Study: 28416836

Group type: EXPERIMENTAL
Intervention: Flexible laryngeal mask airway (FLMA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Reinforced tracheal tube (RTT)
Number of subjects: 120